| Mark L Herring M.d., S.c. | |
|
1355 Johnston Dr Manitowoc WI 54220-2131 | |
| (920) 682-2747 | |
| (920) 686-1498 |
| Full Name | Mark L Herring M.d., S.c. |
|---|---|
| Speciality | Internal Medicine |
| Location | 1355 Johnston Dr, Manitowoc, Wisconsin |
| Authorized Official Name and Position | Mark L Herring (PRESIDENT) |
| Authorized Official Contact | 9206822747 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mark L Herring M.d., S.c. 1355 Johnston Dr Manitowoc WI 54220-2131 Ph: (920) 682-2747 | Mark L Herring M.d., S.c. 1355 Johnston Dr Manitowoc WI 54220-2131 Ph: (920) 682-2747 |
| NPI Number | 1184922320 |
|---|---|
| Provider Enumeration Date | 03/12/2011 |
| Last Update Date | 03/12/2011 |
| Medicare PECOS PAC ID | 9638352081 |
|---|---|
| Medicare Enrollment ID | O20110323000518 |
News Archive
Tengion, Inc. today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal.
As part of its commitment to support research and learning around customer service and the patient experience in healthcare, The Beryl Institute, based in Bedford, Texas, has established The Beryl Institute Patient Experience Grant Program.
The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184922320 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 24825 (Wisconsin) | Primary |
| Provider Name | Mark L Herring |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1386766368 PECOS PAC ID: 3173706520 Enrollment ID: I20110323000537 |
News Archive
Tengion, Inc. today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal.
As part of its commitment to support research and learning around customer service and the patient experience in healthcare, The Beryl Institute, based in Bedford, Texas, has established The Beryl Institute Patient Experience Grant Program.
The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 9 days ago
News Archive
Tengion, Inc. today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal.
As part of its commitment to support research and learning around customer service and the patient experience in healthcare, The Beryl Institute, based in Bedford, Texas, has established The Beryl Institute Patient Experience Grant Program.
The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.
› Verified 9 days ago
Hfm Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1650 S 41st St, Manitowoc, WI 54220 Phone: 920-320-4500 Fax: 920-682-9378 | |
Lakeshore Community Health Care, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 601 Buffalo St, Manitowoc, WI 54220 Phone: 920-686-2333 Fax: 920-783-6392 | |
Hoffman Geriatric Services Sc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2021 S Alverno Rd, Manitowoc, WI 54220 Phone: 920-686-1822 Fax: 920-686-7448 | |
Bellin Memorial Hospital Inc. Dba Fmc Manitowoc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1765 N 18th St, Manitowoc, WI 54220 Phone: 920-482-9394 Fax: 920-482-0579 | |
Fmc Manitowoc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3415 Custer St, Suite D, Manitowoc, WI 54220 Phone: 920-652-9310 | |
Froedtert Northeast Medical Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2300 Western Ave, Manitowoc, WI 54220 Phone: 920-320-2436 |